Endologix Announces Leadership Transition

Dr. John Liddicoat Appointed as President and CEO; Dr. Matt Thompson to Assume New Role as Executive Vice-President and Chief Medical Officer

IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held global medical device company specializing in innovative therapies for vascular disease, today announced a leadership transition. Dr. Matt Thompson will step down as President and Chief Executive Officer and take on a new role as Executive Vice President and Chief Medical Officer. Dr. John Liddicoat has been appointed as the new President and CEO, effective immediately.

Richard Mott, Chairman of the Board stated: “We are thrilled to welcome Dr. John Liddicoat as our new CEO. John’s extensive experience and proven leadership in the healthcare industry make him the ideal person to guide Endologix through its next chapter of growth and innovation. I also want to extend our sincere appreciation to Matt for his exceptional leadership and the significant advancements he has brought to Endologix during his tenure as CEO. We are pleased that Matt will remain an integral part of our team, enabling him to balance his professional commitments with a desire to spend more time in the UK.”

Dr. Liddicoat brings over 30 years of global healthcare experience to his new role. He has served on the boards of several private medical technology companies and advised private equity firms. Notably, Dr. Liddicoat spent more than 16 years in executive roles at Medtronic, where he led strategic initiatives and oversaw global operations for critical divisions, including the cardiac rhythm and heart failure business. He has taken products from concept through product development to global commercial launch. John graduated medical school from the University of Chicago, completed a residency in general and cardiothoracic surgery at Johns Hopkins Hospital, and graduated business school from Boston University.

Dr Liddicoat stated: “I’m excited to join Endologix as President and CEO and build upon the company’s strong foundation. I look forward to collaborating with the team, to expand our impact, and improve outcomes for patients suffering from vascular disease around the world by delivering life-changing vascular solutions.”

About Endologix

Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOUR™ System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com.

Contacts

Media inquiries: media@endologix.com